Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Susan Park Perrine
Boston University
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University College London
London, England, United Kingdom
- Children'S Hospital of Oakland
Oakland, California, United States
- Yale Comprehensive Cancer Center
New Haven, Connecticut, United States
- Clinical Hematology Branch
Bethesda, Maryland, United States
- Boston University School of Medicine
Boston, Massachusetts, United States
- Cancer Research Center
Boston, Massachusetts, United States
- Mount Sinai School of Medicine
New York, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 1999
- Primary completion
- —
- Completion
- —
- Last update posted
- 8 Nov 2005
- Registered enrollment
- 15
- Registry id
- NCT00006136
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.